Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
QuintilesIMS
Accenture
Queensland Health
Boehringer Ingelheim
Chinese Patent Office
Medtronic
Healthtrust
US Department of Justice

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,259,388

« Back to Dashboard

Which drugs does patent 9,259,388 protect, and when does it expire?

Patent 9,259,388 protects GELNIQUE and is included in one NDA.

This patent has nineteen patent family members in thirteen countries.
Summary for Patent: 9,259,388
Title:Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Abstract: The invention relates to a method for treating overactive bladders and a device for storing and administering non-occluded oxybutynin topical compositions.
Inventor(s): Gochnour; Scott (Salt Lake City, UT), Subramanyan; Venkatesh (Salt Lake City, UT), Kimball; Michael W. (Salt Lake City, UT)
Assignee: Watson Pharmaceuticals, Inc. (Salt Lake City, UT)
Application Number:14/059,671
Patent Claim Types:
see list of patent claims
Use; Composition; Device; Formulation;

Drugs Protected by US Patent 9,259,388

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc GELNIQUE oxybutynin chloride GEL;TRANSDERMAL 022204-001 Jan 27, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,259,388

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,920,392 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,259,388

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010246103 ➤ Try a Free Trial
Brazil PI1015542 ➤ Try a Free Trial
Canada 2760867 ➤ Try a Free Trial
Canada 2821174 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Chinese Patent Office
Johnson and Johnson
Colorcon
Express Scripts
Fish and Richardson
Citi
Cerilliant
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.